Loading...
XNAS
PYPD
Market cap40mUSD
Dec 05, Last price  
3.97USD
1D
0.76%
1Q
15.07%
IPO
-99.30%
Name

PolyPid Ltd

Chart & Performance

D1W1MN
XNAS:PYPD chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
67.89%
Rev. gr., 5y
%
Revenues
0k
Net income
-29m
L+21.61%
-1,790,000-3,884,000-8,220,000-11,392,000-54,488,0005,917,0004,750,000-35,324,000-40,713,000-39,525,000-23,865,000-29,022,000
CFO
-22m
L+27.43%
-1,857,000-2,518,0000-9,733,000-12,312,000-16,678,000-17,358,000-21,596,000-32,386,000-34,317,000-17,236,000-21,963,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
URL
http://www.polypid.com
IPO date
Jun 26, 2020
Employees
57
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT